Applicability of the FISH test for bladder cancer.
Fluorescence in situ hybridization (FISH) analysis is an FDA-approved, urine-based marker that assists in diagnosis and surveillance of invasive urothelial cancer. This article provides an overview and case study demonstrating the clinical use of this analysis. As a systematic review of non-randomized and randomized clinical trials, this article provides Level I evidence.
University of Missouri, School of Nursing, Kansas City, MO USA.
Peggy
P
Ward-Smith
Brenda
B
Miller
Michael
M
Caughron
D014408:Biomarkers, Tumor / Q000652:urine; D017281:Cost of Illness; D003558:Cystoscopy; D055317:Evidence-Based Practice; D006801:Humans; D017404:In Situ Hybridization, Fluorescence / Q000379:methods*; D008297:Male; D008875:Middle Aged; D024802:Nurse's Role; D016032:Randomized Controlled Trials as Topic; D012680:Sensitivity and Specificity; D014481:United States / Q000453:epidemiology; D014486:United States Food and Drug Administration; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis* / Q000453:epidemiology / Q000451:nursing / Q000652:urine*
D014408:Biomarkers, Tumor